Caption Management’s Vaxcyte PCVX Stock Holding History

Caption Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-44,200	Closed	-$1.67M	–	1788
2025 Q1	$1.67M	Buy	44,200 +14,200	+47%	+$1.14M	0.02%	748
2024 Q4	$2.46M	Sell	30,000 -24,735	-45%	-$2.46M	0.02%	623
2024 Q3	$6.25M	Buy	+54,735	New	+$4.93M	0.1%	242
2023 Q2	–	Sell	-13,110	Closed	-$621K	–	1328
2023 Q1	$491K	Sell	13,110 -104,190	-89%	-$4.42M	0.01%	799
2022 Q4	$5.62M	Buy	117,300 +58,700	+100%	+$2.3M	0.09%	273
2022 Q3	$1.41M	Buy	+58,600	New	+$1.49M	0.02%	758

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's PCVX Position: Q2 2025 in Review

Caption Management sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 44,200 shares — an estimated $1.67M sold.

Caption Management first reported a position in PCVX in Q3 2022 and held it in 6 quarters. The position peaked at $6.25M in Q3 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Caption Management reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
Caption Management sold 44,200 Vaxcyte shares in Q2 2025, an estimated $1.67M.
Caption Management first reported a position in Vaxcyte in Q3 2022 and held it in 6 quarters.
Caption Management's Vaxcyte position peaked at $6.25M in Q3 2024.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.